Comparative Assessment of Protein Kinase Inhibitors in Public Databases and in PKIDB

Since the first approval of a protein kinase inhibitor (PKI) by the Food and Drug Administration (FDA) in 2001, 55 new PKIs have reached the market, and many inhibitors are currently being evaluated in clinical trials. This is a clear indication that protein kinases still represent major drug targets for the pharmaceutical industry. In a previous work, we have introduced PKIDB, a publicly available database, gathering PKIs that have already been approved (Phase 4), as well as those currently in clinical trials (Phases 0 to 3). This database is updated frequently, and an analysis of the new data is presented here. In addition, we compared the set of PKIs present in PKIDB with the PKIs in early preclinical studies found in ChEMBL, the largest publicly available chemical database. For each dataset, the distribution of physicochemical descriptors related to drug-likeness is presented. From these results, updated guidelines to prioritize compounds for targeting protein kinases are proposed. The results of a principal component analysis (PCA) show that the PKIDB dataset is fully encompassed within all PKIs found in the public database. This observation is reinforced by a principal moments of inertia (PMI) analysis of all molecules. Interestingly, we notice that PKIs in clinical trials tend to explore new 3D chemical space. While a great majority of PKIs is located on the area of “flatland”, we find few compounds exploring the 3D structural space. Finally, a scaffold diversity analysis of the two datasets, based on frequency counts was performed. The results give insight into the chemical space of PKIs, and can guide researchers to reach out new unexplored areas. PKIDB is freely accessible from the following website: http://www.icoa.fr/pkidb.

[1]  Ansgar Schuffenhauer,et al.  Rule‐Based Classification of Chemical Structures by Scaffold , 2011, Molecular informatics.

[2]  Sereina Riniker,et al.  Better Informed Distance Geometry: Using What We Know To Improve Conformation Generation , 2015, J. Chem. Inf. Model..

[3]  Stephen R. Johnson,et al.  Molecular properties that influence the oral bioavailability of drug candidates. , 2002, Journal of medicinal chemistry.

[4]  A. Caflisch,et al.  Current kinase inhibitors cover a tiny fraction of fragment space. , 2015, Bioorganic & medicinal chemistry letters.

[5]  N. Gray,et al.  Targeting cancer with small molecule kinase inhibitors , 2009, Nature Reviews Cancer.

[6]  G. Bemis,et al.  The properties of known drugs. 1. Molecular frameworks. , 1996, Journal of medicinal chemistry.

[7]  Doriano Fabbro,et al.  Ten things you should know about protein kinases: IUPHAR Review 14 , 2015, British journal of pharmacology.

[8]  Petra Schneider,et al.  Privileged Structures Revisited , 2017, Angewandte Chemie.

[9]  W C Guida,et al.  The significance of chirality in drug design and development. , 2011, Current topics in medicinal chemistry.

[10]  Tsuyoshi Arai,et al.  Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents , 2009, Molecular Cancer Therapeutics.

[11]  Gordon M. Crippen,et al.  Prediction of Physicochemical Parameters by Atomic Contributions , 1999, J. Chem. Inf. Comput. Sci..

[12]  Paul Beswick,et al.  What does the aromatic ring number mean for drug design? , 2014, Expert opinion on drug discovery.

[13]  R. Pazdur,et al.  Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[14]  Darko Butina,et al.  Unsupervised Data Base Clustering Based on Daylight's Fingerprint and Tanimoto Similarity: A Fast and Automated Way To Cluster Small and Large Data Sets , 1999, J. Chem. Inf. Comput. Sci..

[15]  Stéphane Bourg,et al.  PKIDB: A Curated, Annotated and Updated Database of Protein Kinase Inhibitors in Clinical Trials , 2018, Molecules.

[16]  Wolfgang H. B. Sauer,et al.  Molecular Shape Diversity of Combinatorial Libraries: A Prerequisite for Broad Bioactivity , 2003, J. Chem. Inf. Comput. Sci..

[17]  E. Van Cutsem,et al.  Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. , 2009, The New England journal of medicine.

[18]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings , 1997 .

[19]  Jürgen Bajorath,et al.  Computational design of new molecular scaffolds for medicinal chemistry, part II: generalization of analog series-based scaffolds , 2017, Future science OA.

[20]  Georgios Giamas,et al.  Protein kinases as targets for cancer treatment. , 2007, Pharmacogenomics.

[21]  Mara Pereira Guerreiro,et al.  Trastuzumab in the Treatment of Breast Cancer , 2016, BioDrugs.

[22]  Stéphane Bourg,et al.  VSPrep: A General KNIME Workflow for the Preparation of Molecules for Virtual Screening , 2017, Molecular informatics.

[23]  Nahum Sonenberg,et al.  Dissecting the role of mTOR: lessons from mTOR inhibitors. , 2010, Biochimica et biophysica acta.

[24]  George Papadatos,et al.  The ChEMBL database in 2017 , 2016, Nucleic Acids Res..

[25]  R. Roskoski.  Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes. , 2016, Pharmacological research.

[26]  Paola Brun,et al.  Quinazoline-based multi-tyrosine kinase inhibitors: synthesis, modeling, antitumor and antiangiogenic properties. , 2013, European journal of medicinal chemistry.

[27]  O. H. Chan,et al.  Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino)quinazoline- and 4-(phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizing functions. , 2000, Journal of medicinal chemistry.

[28]  T. Hunter,et al.  The Protein Kinase Complement of the Human Genome , 2002, Science.

[29]  P. Cohen,et al.  Immune diseases caused by mutations in kinases and components of the ubiquitin system , 2014, Nature Immunology.

[30]  Helmut Mack,et al.  Rho kinase, a promising drug target for neurological disorders , 2005, Nature Reviews Drug Discovery.

[31]  C. Humblet,et al.  Escape from flatland: increasing saturation as an approach to improving clinical success. , 2009, Journal of medicinal chemistry.

[32]  T. Halgren.  Merck molecular force field. I. Basis, form, scope, parameterization, and performance of MMFF94 , 1996, J. Comput. Chem..

[33]  Evan Bolton,et al.  PubChem 2019 update: improved access to chemical data , 2018, Nucleic Acids Res..

[34]  R. Roskoski.  Properties of FDA-approved small molecule protein kinase inhibitors. , 2019, Pharmacological research.

[35]  Jürgen Bajorath,et al.  Assessing Scaffold Diversity of Kinase Inhibitors Using Alternative Scaffold Concepts and Estimating the Scaffold Hopping Potential for Different Kinases , 2017, Molecules.

[36]  T. N. Bhat,et al.  The Protein Data Bank , 2000, Nucleic Acids Res..

[37]  H. Rupasinghe,et al.  Kinase-targeted cancer therapies: progress, challenges and future directions , 2018, Molecular Cancer.

[38]  Gaël Varoquaux,et al.  Scikit-learn: Machine Learning in Python , 2011, J. Mach. Learn. Res..